Tags : Worldwide

Pharma

Nestle Health Science Signs a Worldwide Exclusive Agreement with VALBIOTIS

Shots: VALBIOTIS to receive ~$5.1M up front, ~$67.7 as development & commercial milestones and royalties on sales of therapy. Nestle to get exclusive global rights to commercialize TOTUM-63 in the prediabetes and T2D market The companies will jointly deal with clinical development, regulatory matters, supply and commercialization of the therapy. Additionally, VALBIOTIS will supply TOTUM-63 […]Read More

MedTech

Inotrem Signs a Worldwide License agreement with Roche Diagnostic for

Shots: Inotrem enters into a global licensing agreement with Roche Diagnostics to commercialize mechanism-based CDx test utilizing a soluble plasma protein (sTREM-1) The collaboration leads towards the enhancement of Inotrem’s approach targeting TREM-1 pathway and allows it to focus on the development of a nangibotide-based septic shock treatment LR12 (nangibotide) is the first-in-class TREM-1 inhibitor […]Read More

Pharma

Immunic Exercises its Worldwide Exclusive Option to License for IMU-856

Shots: Immunic has exercised its exclusive option to license a group of compounds for Daiichi’s IMU-856. Daiichi to receive up front, certain future development, approval & sales milestone payments plus royalties on IMU-856. Immunic to get exclusive commercialization rights for IMU-856 in all countries, including the US, EU, and Japan Additionally, the option includes patent […]Read More

Pharma

Merck & Co. Signs an Exclusive Worldwide License Agreement with

Shots: Taiho and Astex to receive $50M up front, up to $2.5B milestones based on preclinical, clinical, regulatory and sales plus royalties on sales. Merck (MSD outside the United States and Canada) to get exclusive worldwide rights to commercialize Taiho and Astex’s therapies and will also fund the R&D activities Additionally, the companies will combine […]Read More

Pharma

Pfizer Signs a Worldwide License Agreement with Theravance BioPharma for

Shots: Theravance to receive $10M up front, up to $240M development & commercial milestones with royalties on global sales of any product developed from the program. Pfizer to get a global license for Theravance’s skin-targeted, LA, pan-Janus kinase (JAK) inhibitors   Pfizer will validate Theravance’s expertise in the discovery & development of organ-selective JAK inhibitors […]Read More

Pharma

Celgene Signs an Exclusive Worldwide License Agreement with Skyhawk to

Shots: Skyhawk to receive $80M up front, milestones, and royalties on sales. Celgene to get exclusive WW option to license IPR for the number of Skyhawk’s candidates targeting multiple autoimmune disorder, oncology, and immuno-oncology targets. Post option exercising, Celgene will be responsible for further development and commercialization of products In 2018, the companies collaborated to […]Read More

Pharma

Novo Nordisk Signs an Exclusive Worldwide License Agreement with UBE

Shots: UBE to receive up front, development & commercial milestones and royalties on sales. Novo Nordisk to get exclusive WW license to UBE’s preclinical asset UD-014 and will be responsible for development, manufacturing and commercialization of UD-014 The collaboration will widen Novo Nordisk’s presence and investment in NASH and will provide more treatment options to […]Read More

MedTech

Promega Signs a Worldwide Agreement with Merck to Develop MSI

Shots: Promega and Merck collaborated to develop Promega’s microsatellite instability (MSI) technology as an on-label solid tumor CDx for use with Merck’s Keytruda (pembrolizumab)  Promega’s Microsatellite Instability technology measures the genomic accumulation of insertion or deletion (INDEL) errors caused by a deficient mismatch-repair system (dMMR) occurring in a solid-tumors, used to characterize tumors and guide […]Read More